ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress

@inproceedings{Neumann2018ctDNAAC,
  title={ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress},
  author={Martin H.D. Neumann and Sebastian Bender and Thomas A. Krahn and Thomas Schlange},
  booktitle={Computational and structural biotechnology journal},
  year={2018}
}
We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview of corresponding technologies is given. 
BETA

Similar Papers

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 64 REFERENCES

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
VIEW 2 EXCERPTS

Clinical application of liquid biopsy in targeted therapy of metastatic colorectal cancer

J Trojan
  • Case Rep Oncol Med
  • 2017
VIEW 1 EXCERPT

Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: a systematic review and meta-analysis

J Nian
  • Clin Transl Gastroenterol
  • 2017

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling

AA Chaudhuri
  • Cancer Discov
  • 2017
VIEW 1 EXCERPT